Malignancy and hypercoagulability: a two-way association revisited

Abstract

Increasing evidence is highlighting the relationship between malignancy and hypercoagulability as a bidirectional association. We herein share our experience with a patient in whom such an association may be entertained. The patient, who had a history of venous thromboembolism, presented to our care with manifestation of stroke. Extensive workup revealed that the patient carries prothrombotic mutations in the prothrombin and methylenetetrahydrofolate reductase genes. The patient, a non-smoker, was also diagnosed with non-small cell lung carcinoma. The possible association between the patient’s malignancy and prothrombotic state are further discussed.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Agnelli G, Verso M (2005) Thrombosis and cancer: clinical relevance of a dangerous liaison. Haematologica 90:155–156

    Google Scholar 

  2. 2.

    Franchini M, Veneri D, Salvagno GL et al (2006) Inherited thrombophilia. Crit Rev Clin Lab Sci 43:249–290

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Hankey GJ, Eikelboom JW, van Bockxmeer FM et al (2001) Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke 32:1793–1799

    CAS  PubMed  Google Scholar 

  4. 4.

    Graus F, Rogers LR, Posner JB (1985) Cerebrovascular complications in patients with cancer. Medicine (Baltimore) 64:16–35

    CAS  Google Scholar 

  5. 5.

    Taccone FS, Jeangette SM, Blecic SA (2008) First-ever stroke as initial presentation of systemic cancer. J Stroke Cerebrovasc Dis 17:169–174

    Article  PubMed  Google Scholar 

  6. 6.

    Decousus H, Moulin N, Quenet S et al (2007) Thrombophilia and risk of venous thrombosis in patients with cancer. Thrombosis Res 120(Suppl 2):S51–S61

    Article  Google Scholar 

  7. 7.

    Rickles FR, Patierno S, Fernandez PM (2003) Tissue factor, thrombin, and cancer. Chest 124(Suppl 3):S58–S68

    Article  Google Scholar 

  8. 8.

    Vairaktaris E, Yapijakis C, Wiltfang J et al (2005) Are factor V and prothrombin mutations associated with increased risk of oral cancer? Anticancer Res 25:2561–2565

    CAS  PubMed  Google Scholar 

  9. 9.

    Batistelli S, Stefanoni M, Genovese A et al (2006) Prevalence of factor V leiden and prothrombin G20210A in patients with gastric cancer. World J Gastrornterol 12:4179–4180

    Google Scholar 

  10. 10.

    Smorenburg SM, Van Noorden CJF (2001) The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 53:93–105

    CAS  PubMed  Google Scholar 

  11. 11.

    Kuderer NM, Khorana AA, Lyman GH, Francis CW (2007) A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 110:1149–1160

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Ali T. Taher.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Aoun, E.G., Musallam, K.M., Abou-Ghazal, M. et al. Malignancy and hypercoagulability: a two-way association revisited. J Thromb Thrombolysis 30, 340–341 (2010). https://doi.org/10.1007/s11239-010-0458-4

Download citation

Keywords

  • Hypercoagulability
  • Lung cancer
  • Malignancy
  • Stroke
  • Thrombophilia
  • Venous thromboembolism